Lisata Therapeutics Announces Participation in Upcoming Conferences in February
February 01 2023 - 8:30AM
Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the
“Company”), a clinical-stage pharmaceutical company developing
innovative therapies for the treatment of advanced solid tumors and
other serious diseases, today announced that management will
present at two upcoming conferences. Details of the events are as
follows:
2023 BIO CEO & Investor ConferenceFebruary
6-9, 2023 | New York, NY
David J. Mazzo, PhD, Chief Executive Officer of Lisata, will
deliver a live presentation on Tuesday, February 7, 2023, at 2:00
p.m. Eastern time. Management will also participate in one-on-one
meetings with investors throughout the conference. For more
information about the 2023 BIO CEO & Investor Conference,
please visit www.bio.org/events/bio-ceo-investor-conference.
Biocom California’s 13th Annual Global Life Science
Partnering & Investor Conference February 28 – March
2, 2023 | La Jolla, California
David S. Slack, President and Chief Business Officer of Lisata,
will deliver a live presentation on Wednesday, March 1, 2023, at
2:57 p.m. Pacific time. Management will also participate in
one-on-one meetings with investors throughout the conference. For
more information about Biocom California’s Global Life Science
Partnering & Investor Conference, please visit
www.biocom.org/conferences/global-partnering-conference.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company
dedicated to the discovery, development, and commercialization of
innovative therapies for the treatment of advanced solid tumors and
other major diseases. Lisata’s lead investigational product
candidate, LSTA1 (formerly known as CEND-1), is designed to modify
the tumor microenvironment by activating a novel uptake pathway
that allows anti-cancer drugs to penetrate solid tumors more
effectively. LSTA1 actuates an active transport system in a
tumor-specific manner, resulting in systemically co-administered
anti-cancer drugs more efficiently penetrating and accumulating in
the tumor, while normal tissues are not affected. LSTA1 has
demonstrated favorable safety, tolerability, and activity in
clinical trials to enhance delivery of standard-of-care
chemotherapy for pancreatic cancer. Lisata and its collaborators
have also amassed significant non-clinical data demonstrating
enhanced delivery of a range of emerging anti-cancer therapies,
including immunotherapies and RNA-based therapeutics. Lisata is
exploring the potential of LSTA1 to enable a variety of treatment
modalities to treat a range of solid tumors more effectively. In
addition, Lisata also has clinical development programs based on
its autologous CD34+ cell therapy technology platform. For more
information on the Company, please visit www.lisata.com.
Contact:
Investors and Media:Lisata Therapeutics, Inc.John MendittoVice
President, Investor Relations and Corporate
CommunicationsPhone: 908-842-0084Email: jmenditto@lisata.com
Lisata Therapeutics (NASDAQ:LSTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lisata Therapeutics (NASDAQ:LSTA)
Historical Stock Chart
From Apr 2023 to Apr 2024